DNA‐Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice

Koga, Yoshinori; Sotokawauchi, Ami; Higashimoto, Yuichiro; Nishino, Yoshinori; Hashizume, Naoki; Kakuma, Tatsuyuki; Akiba, Jun; Tanaka, Yoshiaki; Matsui, Takanori; Yagi, Minoru; Yamagishi, Sho‐ichi

doi:10.1155/2021/9932311

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During sepsis, endothelial permeability is severely augmented, which promotes kidney injury. Koga et al revealed that neutralization of RAGE improved the survival rate of LPS–induced septic mice with a reduction in HMGB–1 concentration and ROS production ( Koga et al, 2021 ). The protective effect of RAGE inhibition in sepsis can be explained by the restoration of endothelial permeability.…”

Section: Rage Mediates Endothelial Permeability In Diabetic Conditionsmentioning

confidence: 99%

RAGE signaling regulates the progression of diabetic complications

Taguchi

Fukami

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Diabetes, the ninth leading cause of death globally, is expected to affect 642 million people by 2040. With the advancement of an aging society, the number of patients with diabetes having multiple underlying diseases, such as hypertension, obesity, and chronic inflammation, is increasing. Thus, the concept of diabetic kidney disease (DKD) has been accepted worldwide, and comprehensive treatment of patients with diabetes is required. Receptor for advanced glycation endproducts (RAGE), a multiligand receptor, belonging to the immunoglobulin superfamily is extensively expressed throughout the body. Various types of ligands, including advanced glycation endproducts (AGEs), high mobility group box 1, S100/calgranulins, and nucleic acids, bind to RAGE, and then induces signal transduction to amplify the inflammatory response and promote migration, invasion, and proliferation of cells. Furthermore, the expression level of RAGE is upregulated in patients with diabetes, hypertension, obesity, and chronic inflammation, suggesting that activation of RAGE is a common denominator in the context of DKD. Considering that ligand–and RAGE–targeting compounds have been developed, RAGE and its ligands can be potent therapeutic targets for inhibiting the progression of DKD and its complications. Here, we aimed to review recent literature on various signaling pathways mediated by RAGE in the pathogenesis of diabetic complications. Our findings highlight the possibility of using RAGE–or ligand–targeted therapy for treating DKD and its complications.

show abstract

Section: Rage Mediates Endothelial Permeability In Diabetic Conditionsmentioning

confidence: 99%

RAGE signaling regulates the progression of diabetic complications

Taguchi

Fukami

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…A growing body of experimental data using the DNA-aptamer technology against RAGE has demonstrated that this novel approach can inhibit the inflammatory reactions triggered by activation of the RAGE axis in different in vivo models[ 91 - 93 ].…”

Section: Therapeutic Potential Of the Rage/ages Axis In Tumor Biologymentioning

confidence: 99%

Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider

Rojas¹,

Lindner²,

Schneider³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

Compelling evidence derived from clinical and experimental research has demonstrated the crucial contribution of chronic inflammation in the development of neoplasms, including gallbladder cancer. In this regard, data derived from clinical and experimental studies have demonstrated that the receptor of advanced glycation end-products (RAGE)/AGEs axis plays an important role in the onset of a crucial and long-lasting inflammatory milieu, thus supporting tumor growth and development. AGEs are formed in biological systems or foods, and food-derived AGEs, also known as dietary AGEs are known to contribute to the systemic pool of AGEs. Once they bind to RAGE, the activation of multiple and crucial signaling pathways are triggered, thus favoring the secretion of several proinflammatory cytokines also involved in the promotion of gallbladder cancer invasion and migration. In the present review, we aimed to highlight the relevance of the association between high dietary AGEs intakes and high risk for gallbladder cancer, and emerging data supporting that dietary intervention to reduce gallbladder cancer risk is a very attractive approach that deserves much more research efforts.

show abstract

Role and Therapeutic Potential of RAGE Signaling in Neurodegeneration

Kinscherf

Pehar

2022

CDT

View full text Add to dashboard Cite

Activation of the receptor for advanced glycation end products (RAGE) has been shown to play an active role in the development of multiple neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Although originally identified as a receptor for advanced glycation end products, RAGE is a pattern recognition receptor able to bind multiple ligands. The final outcome of RAGE signaling is defined in a context and cell type specific manner and can exert both neurotoxic and neuroprotective functions. Contributing to the complexity of the RAGE signaling network, different RAGE isoforms with distinctive signaling capabilities have been described. Moreover, multiple RAGE ligands bind other receptors and RAGE antagonism can significantly affect their signaling. Here, we discuss the outcome of cell-type specific RAGE signaling in neurodegenerative pathologies. In addition, we will review the different approaches that have been developed to target RAGE signaling and their therapeutic potential. A clear understanding of the outcome of RAGE signaling in a cell type- and disease-specific manner would contribute to advance the development of new therapies targeting RAGE. The ability to counteract RAGE neurotoxic signaling while preserving its neuroprotective effects would be critical for the success of novel therapies targeting RAGE signaling.

show abstract

DNA‐Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice

Cited by 3 publications

References 42 publications

RAGE signaling regulates the progression of diabetic complications

RAGE signaling regulates the progression of diabetic complications

Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider

Role and Therapeutic Potential of RAGE Signaling in Neurodegeneration

Contact Info

Product

Resources

About